Archive
Every story, newest first.
Saturday, November 7, 2026
Rates
Bank of Japan Governor Kazuo Ueda told the IMF's Camdessus lecture on Friday that Japan's current account surplus, still 2 to 4 percent of GDP, is now carried by overseas investment income above 6 percent of GDP rather than by exports, and offered no new signal on monetary policy.
Rates
Czech Prime Minister Andrej Babis was reported to have called the central bank's latest rate increase scandalous, Paraguay's Ueno Bank depositors began receiving guarantee transfers, and the Bank of Canada's summary of deliberations is due on November 10.
Rates
San Francisco Fed President Mary Daly said on Friday that further rate increases are likely to be needed, hours after October payrolls rose 165,000, while New York Fed President John Williams urged gathering more information and the White House argued the jobs report is no reason to hike.
Life Sciences
Following FDA feedback, Satellos Bioscience has made change in MRI measured muscle fat fraction the primary efficacy endpoint of its Phase 2 BASECAMP trial of forazapadin in 53 boys with Duchenne muscular dystrophy.
Life Sciences
Sarepta Therapeutics will not resume enrollment in ENVISION, the Phase 3 confirmatory trial for its Duchenne gene therapy Elevidys, which enrolled 90 participants and has been on global hold for more than a year.
Life Sciences
Moderna reported third quarter net income of 162 million dollars on revenue of 1.31 billion dollars, up 29 percent year on year, against a net loss of 200 million dollars a year earlier.
Life Sciences
Eli Lilly will sell its obesity medicines Zepbound and Foundayo directly through the Hims and Hers telehealth platform at self pay prices starting at 299 dollars and 149 dollars a month.
Life Sciences
In a Phase 1/2 study, Immunocore's brenetafusp combined with Kimmtrak produced a 29 percent response rate and an estimated 70 percent two year survival rate in 17 evaluable first line patients with metastatic uveal melanoma.
Life Sciences
Oregon, Minnesota, New Mexico and Washington sued the Trump administration on November 5 to block Medicaid work requirements that take effect on January 1, 2027, arguing the conditions exceed Congress's spending power.
Life Sciences
Alnylam's chief commercial officer is leaving amid Amvuttra sales concerns, ANI Pharmaceuticals offered 560 million dollars for Sweden's Egetis Therapeutics, and Ultragenyx will cut 1,000 jobs after its Angelman gene therapy failed.